Azerbaijan vs Burkina Faso: Access to anti-retroviral drugs, female
Azerbaijan
98.0%
in 2024
Burkina Faso
98.0%
in 2024
Azerbaijan rank
1st
Burkina Faso rank
1st
Access to anti-retroviral drugs, female over time
- Azerbaijan
- Burkina Faso
How they compare
Azerbaijan currently reports 98.0% against 98.0% in Burkina Faso, a difference of 0.0%.
Across all 24 years both countries report, Burkina Faso has been ahead every year.
Azerbaijan ranks 1st and Burkina Faso ranks 1st of 141 countries.
Burkina Faso has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Azerbaijan | Burkina Faso | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.0% | 10.2% | 9.2% | Burkina Faso |
| 2010s | 32.0% | 67.6% | 35.6% | Burkina Faso |
| 2020s | 83.6% | 91.8% | 8.2% | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Azerbaijan or Burkina Faso?
- Azerbaijan, at 98.0% against 98.0% in Burkina Faso as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Azerbaijan and Burkina Faso?
- 0.0%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and Burkina Faso?
- 24 years are reported by both, from 2000 to 2024.
- How do Azerbaijan and Burkina Faso rank globally for access to anti-retroviral drugs, female?
- Azerbaijan ranks 1st and Burkina Faso ranks 1st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.